Institutional members access full text with Ovid®

Share this article on:

Congenital Neuroblastoma in a Neonate With Isotretinoin Embryopathy

Aguilar, Shiley MSN, RN, FNP-C; Louis, Chrystal MD, MPH; Hicks, John MD, DDS, PhD; Zage, Peter MD, PhD; Russell, Heidi MD

Journal of Pediatric Hematology/Oncology: March 2014 - Volume 36 - Issue 2 - p e75–e77
doi: 10.1097/MPH.0b013e318290c39e
Online Articles: Clinical and Laboratory Observations

We describe a neonate with isotretinoin embryopathy and an incidental finding of congenital neuroblastoma. Diffuse liver metastases led to the decision to provide oncologic therapy followed by tumor resection. Despite the possible need for chronic care related to the comorbidities of the isotretinoin embryopathy and oncologic management, the patient remains disease-free. Because of the uncertain etiology of neuroblastoma, it remains unclear whether exposure to isotretinoin during embryogenesis and fetal development had an oncogenic effect on this patient.

*Texas Children’s Cancer Center

Department of Pathology, Baylor College of Medicine, Houston, TX

C.L. has Royalties from Cell Medica. P.Z. has an Independent Medical Grant from EMD Serono Inc. The remaining authors declare no conflict of interest.

Reprints: Shiley Aguilar, MSN, RN, FNP-C, Texas Children’s Cancer Center, Baylor College of Medicine, 6701 Fannin St., Suite 1500, Houston, TX 77030 (e-mail: slaguil1@txch.org).

Received July 11, 2012

Accepted February 26, 2013

Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.